Imbed Biosciences has developed wound-conforming, dissolvable microfilm dressings for use in tissue repair and regenerative medicine. Its first product, Microlyte Ag, already has FDA approval as a hydrogel dressing for use in the advanced wound care market.
The company was founded by a notable group of University of Wisconsin-Madison researchers with expertise in ultrathin dissolvable microfilms. Initial development has focused on advanced wound care with additional proprietary products targeted for use with surgical devices and for sustained delivery of biofilm suppressants, analgesics and other pain management solutions.
In August 2016, Imbed received FDA approval on its first of its kind silver dressing that is safe for use in wound treatment without the risk of silver toxicity or staining. In September 2016, Imbed received ISO 1345 Certification on it manufacturing process.
Infections in hard-to-heal wounds affect more than 20 million patients in the U.S. and E.U. annually. Antimicrobial wound dressings are a $1.5 billion market in the U.S. and Western Europe alone, growing at 20% compounded annually.
David Guinther represents the best interests of our LPs as a member of the Imbed Board of Directors.
For more information about Imbed Biosciences, please visit http://www.imbedbio.com/.